Does UnitedHealthcare Cover Saxenda?

UnitedHealthcare Formulary Placement for Saxenda

On most UnitedHealthcare commercial PPO and HMO formularies, Saxenda sits at Tier 3. That means it is a non-preferred brand medication, which carries a higher copay or coinsurance than Tier 1 (generics) or Tier 2 (preferred brands) drugs. In practical terms, commercially insured UHC members typically pay between $75 and $250 per month out of pocket after prior authorization is approved, though exact cost-sharing depends on the specific plan's benefit design.

Tier 3 placement is common across large insurers for GLP-1 receptor agonists approved for weight management. UHC's pharmacy and therapeutics committee evaluates clinical evidence and cost when assigning tiers. Saxenda (liraglutide 3 mg) earned its FDA approval for chronic weight management in December 2014 based on the SCALE clinical program, which demonstrated meaningful weight reduction compared to placebo in adults with obesity or overweight with at least one weight-related comorbidity [1]. The SCALE Obesity and Prediabetes trial (N=3,731) showed that liraglutide 3 mg produced a mean weight loss of 8.0% of body weight at 56 weeks versus 2.6% for placebo [1]. Because Saxenda's list price is $1,349 per month, insurers apply utilization management controls to limit spending. That is why prior authorization is not optional on UHC plans.

Employer-sponsored plans that use UHC as their pharmacy benefit manager may customize their formulary. Some large employers exclude anti-obesity medications entirely from coverage. Before assuming your plan covers Saxenda, call the number on the back of your insurance card or log in to myuhc.com to view your specific formulary and benefit summary document.

Prior Authorization Criteria UnitedHealthcare Requires

UHC's prior authorization for Saxenda is rated moderate in difficulty. Your prescriber will need to submit clinical documentation proving you meet specific criteria. The typical PA checklist includes a confirmed BMI of 30 or higher (or 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia), documentation of a structured diet and exercise program lasting at least three to six months that failed to produce adequate weight loss, and a statement from the prescribing clinician supporting medical necessity.

The FDA label for Saxenda specifies it as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults [2]. UHC mirrors this language in its coverage policy. Your provider should reference the FDA-approved indication directly when completing the PA form.

PA turnaround is usually five to ten business days for standard requests. Urgent or expedited reviews can return a decision within 72 hours. If your pharmacy submits a claim and it is rejected at the point of sale, the rejection code will indicate that PA is required, and your prescriber's office can initiate the process electronically through the UHC provider portal.

One detail that catches patients off guard: the PA approval is typically valid for 12 months, after which a renewal is required. At renewal, UHC may ask for evidence of continued weight loss (usually defined as at least 4% of baseline body weight lost within the first 16 weeks of therapy, consistent with the Saxenda prescribing information's recommendation to discontinue if that threshold is not met) [2].

Step Therapy: What UnitedHealthcare May Require First

Many UHC plans enforce step therapy for Saxenda. Step therapy means you must try and fail (or demonstrate intolerance to) a lower-cost or first-line weight management medication before UHC will authorize Saxenda. The most commonly required "first step" agents include orlistat (Alli/Xenical) and, in some plan designs, phentermine.

Step therapy exists because the Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommends considering approved anti-obesity medications as an addition to lifestyle intervention when lifestyle changes alone are insufficient [3]. UHC's clinical policy uses this guideline framework to justify requiring trial of at least one less expensive option.

What counts as a "fail"? Typically, 90 days of documented use of the step-therapy drug with inadequate weight loss (less than 5% of body weight) or documented adverse effects that make continuation inappropriate. Your prescriber should document this clearly in the medical record and include it in the PA submission. If you have a contraindication to orlistat (for example, chronic malabsorption syndrome or cholestasis), that can qualify as a clinical exception to bypass the step.

Some UHC plans waive step therapy if the member has a BMI of 40 or above, or if the member has type 2 diabetes and the prescriber can argue clinical urgency. These exceptions are plan-specific and not guaranteed.

How to Appeal a UnitedHealthcare Denial for Saxenda

A denied PA is not the end. UHC provides a structured, three-level appeal process: two internal levels and one external review through an independent review organization (IRO).

First-level internal appeal. Your prescriber (or you, as the member) submits a written appeal within 180 days of the denial. Include any new clinical documentation, lab results, or a letter of medical necessity from your provider. Reference the specific clinical evidence supporting Saxenda use in your case. Citing the SCALE trial data, specifically the 8.0% mean body weight reduction at 56 weeks versus 2.6% with placebo [1], and the FDA-approved indication gives the appeal medical grounding.

Second-level internal appeal. If the first appeal is denied, you may request a second review. This review is conducted by a physician reviewer who was not involved in the original denial. Include a peer-to-peer review request, which allows your prescriber to speak directly with UHC's medical director. Peer-to-peer calls overturn denials more frequently than paper appeals alone.

External IRO review. If both internal appeals fail, you have the right to an external review by an independent third party. The IRO decision is binding on UHC. According to the Department of Labor's guidance on external review under the ACA, external review must be available for any adverse benefit determination involving medical necessity [4]. Your state insurance department can also assist with filing the external review request.

Timeline matters. First-level appeals are typically decided within 30 calendar days. Expedited appeals (when delay could seriously jeopardize your health) must be decided within 72 hours. Keep copies of every submission and note every reference number.

The Real Cost: What You Will Pay Out of Pocket

Without insurance, Saxenda costs $1,349 per month at the manufacturer's list price. That is $16,188 per year. With UHC Tier 3 coverage, your actual cost depends on your plan's copay or coinsurance structure.

Plans with a flat copay for Tier 3 drugs typically charge $75 to $150 per fill. Plans with percentage-based coinsurance (common in high-deductible health plans) may charge 25% to 50% of the negotiated price, which could mean $200 to $400 per month until the deductible and out-of-pocket maximum are met.

The manufacturer, Novo Nordisk, offers a savings card program that can reduce out-of-pocket costs to as little as $25 per month for commercially insured patients. This card is not valid for government-funded insurance (Medicare Part D, Medicaid, Tricare). Eligibility requirements are on the official Saxenda savings card website. The savings card can be combined with your UHC commercial plan benefit, and it applies after your insurance processes the claim.

One strategy to reduce cost: if your UHC plan applies Saxenda to the deductible before copay kicks in, the savings card can offset a portion of that deductible-phase cost. Ask your pharmacy to run the savings card as a secondary payer.

A 2022 analysis published in Obesity found that out-of-pocket costs are the primary reason patients discontinue GLP-1 receptor agonists for weight management within the first six months, with 42% of patients citing cost as the reason for stopping therapy [5]. Securing insurance coverage and using available copay assistance can meaningfully improve adherence.

Saxenda vs. Newer GLP-1 Options on UnitedHealthcare

Saxenda is a once-daily injectable GLP-1 receptor agonist. Newer agents in the same class, particularly semaglutide 2.4 mg (Wegovy), have entered the market and in some cases displaced Saxenda on insurer preferred drug lists. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [6]. That result exceeds Saxenda's 8.0% at 56 weeks from SCALE [1].

UHC formulary positioning between Saxenda and Wegovy varies by plan year and employer. Some 2026 UHC formularies list Wegovy as the preferred GLP-1 for weight management, which could push Saxenda to a higher tier or require additional step therapy. If your prescriber believes Saxenda is the right choice for your clinical situation (for example, if you have previously tolerated liraglutide well at the 1.8 mg diabetes dose, or if Wegovy is in shortage), the PA submission should explain why Saxenda is medically necessary despite alternative options.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on obesity management recommends selecting anti-obesity medications based on individual patient factors including comorbidity profile, prior medication history, and patient preference [7]. This guidance supports the argument that formulary tier should not be the sole determinant of drug selection.

Medicare and Medicaid: A Different Situation

If you have UnitedHealthcare Medicare Advantage (AARP or other branded plans), Saxenda coverage is extremely limited. Medicare Part D has historically excluded coverage for anti-obesity medications under the statutory exclusion for weight loss drugs. The Treat and Reduce Obesity Act, if passed, would change this, but as of mid-2026, the exclusion remains in effect for most Medicare beneficiaries.

UHC Medicaid (community plans) coverage for Saxenda varies by state. Some state Medicaid programs cover FDA-approved anti-obesity medications; others do not. Check your state's Medicaid preferred drug list or call UHC Community Plan member services directly.

Practical Steps to Get Saxenda Covered by UnitedHealthcare

Start with documentation. Before your prescriber submits the PA, make sure your chart includes a recent BMI measurement, a list of weight-related comorbidities with supporting labs (fasting glucose, HbA1c, lipid panel, blood pressure readings), documentation of prior diet and exercise attempts (ideally a referral to a registered dietitian or a structured program), and records of any prior anti-obesity medications tried with dates, doses, and outcomes.

Your prescriber should use the ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.09 as the primary diagnosis. Pairing this with relevant comorbidity codes (E11 for type 2 diabetes, I10 for hypertension) strengthens the medical necessity argument.

Request that your prescriber's office submit the PA electronically through the UHC provider portal (UHCProvider.com) rather than by fax. Electronic submissions are processed faster and have a lower rate of administrative denial due to incomplete forms.

If the PA is approved, fill your prescription promptly. PA approvals have a window (typically 30 days for the initial fill), and an expired PA means restarting the process. Set a calendar reminder for 10 to 11 months after approval to initiate the renewal PA before it lapses.